

Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer: elevated Th2/Th9 cytokine production before and reduced Th2 cytokine production after radioactive iodine therapy

Snezana Zivancevic Simonovic · Olgica Mihaljevic · Ivana Majstorovic · Predrag Djurdjevic · Irena Kostic · Olivera Milosevic Djordjevic · Ljiljana Mijatovic Teodorovic

Received: 25 June 2014 / Accepted: 29 September 2014 / Published online: 9 October 2014
© Springer-Verlag Berlin Heidelberg 2014

Abstract Cytokines play a key role in the regulation of cells of the immune system and also have been implicated in the pathogenesis of malignant diseases. The aim of this study was to evaluate cytokine profiles in patients with differentiated thyroid cancer (DTC) before and 7 days after radioactive iodine (^{131}I) therapy. Cytokine levels were determined in supernatants obtained from phytohemagglutinin-stimulated whole blood cultures of 13 patients with DTC and 13 control subjects. The concentrations of selected cytokines: Th1—interferon gamma ($\text{IFN-}\gamma$), interleukin 2 (IL-2) and tumor necrosis factor alpha ($\text{TNF-}\alpha$); Th2—interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 13 (IL-13) and interleukin 10 (IL-10); Th9—interleukin-9 (IL-9); and Th17—interleukin 17 (IL-17A) were measured using multiplex cytokine detection systems for Human Th1/Th2/Th9/Th17/Th22. We have shown that peripheral blood cells of DTC patients produce significantly higher concentrations of Th2/Th9 cytokines (IL-5, IL-13 and IL-9) than control subjects. The ^{131}I therapy led to reduced secretion of Th2 cytokines (IL-4, IL-5 and IL-13). Despite this, the calculated cytokine ratios (Th1/Th2) in DTC patients before and 7 days after ^{131}I therapy were not different

from those in healthy subjects. DTC patients have significantly higher concentrations of Th2/Th9 cytokines (IL-5, IL-13 and IL-9) than control subjects. There is no influence of hypothyroidism or stage of disease on cytokine production in DTC patients before ^{131}I therapy. The radioactive ^{131}I therapy leads to reduced secretion of Th2 cytokines (IL-4, IL-5 and IL-13). Additional studies are needed to determine the significance of these findings.

Keywords Cytokines · Differentiated thyroid cancer · Radioactive iodine therapy · Th1/Th2 ratio

Abbreviations

^{131}I	Iodine 131
DTC	Differentiated thyroid cancer
EANM	European Association of Nuclear Medicine
$\text{IFN-}\gamma$	Interferon gamma
IL-2	Interleukin 2
IL-4	Interleukin 4
IL-5	Interleukin 5
IL-9	Interleukin 9
IL-10	Interleukin 10
IL-13	Interleukin 13
IL-17A	Interleukin 17A
PHA	Phytohemagglutinin
SD	Standard deviation
Th1	T-helper-1
Th2	T-helper-2
Th9	T-helper-9
Th17	T-helper-17
$\text{TNF-}\alpha$	Tumor necrosis factor alpha
TSH	Thyroid-stimulating hormone
TxN0M0	Patients without any proven metastases
TxNxM0	Patients with nodal metastases

S. Z. Simonovic (✉) · O. Mihaljevic · P. Djurdjevic · I. Kostic · O. M. Djordjevic · L. M. Teodorovic
Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovica 69, 34000 Kragujevac, Serbia
e-mail: snezana@medf.kg.ac.rs

I. Majstorovic
Institute for Medical Research, Military Medical Academy, Belgrade, Serbia

L. M. Teodorovic
Department of Nuclear Medicine, Clinical Center Kragujevac, Kragujevac, Serbia

